{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T11:09:37Z","timestamp":1778670577753,"version":"3.51.4"},"reference-count":33,"publisher":"Walter de Gruyter GmbH","issue":"2","license":[{"start":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T00:00:00Z","timestamp":1776902400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Fundacion J.L.Castano-SEQC"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_almed-2025-0180_abs_001\">\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>Rheumatoid arthritis (RA) is a chronic inflammatory disease of immune-mediated origin. Janus kinase inhibitors (JAK inhibitors) have expanded therapeutic options in recent years; however, clinical response varies among patients, and no biomarkers are currently available to predict their efficacy. The aim of this study was to analyze the association between pharmacogenetic variants and clinical response to JAK inhibitors in patients with\u00a0RA.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_almed-2025-0180_abs_002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An observational, ambispective, single-center study was conducted in adult patients diagnosed with RA and treated with JAK inhibitors. Sociodemographic and clinical characteristics were collected from electronic medical records. Five genetic variants previously associated with response to biological therapies in RA were analyzed through genotyping.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_almed-2025-0180_abs_003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      A total of 56 patients were included in the study. A statistically significant association was observed between the rs20575 variant of the\n                      <jats:italic>TNFRSF10A<\/jats:italic>\n                      gene and clinical remission, with CG or CC genotypes being more frequent among patients who achieved remission at the last available follow-up. Additionally, the rs1801274 polymorphism of the\n                      <jats:italic>FCGR2A<\/jats:italic>\n                      gene was associated with a lower likelihood of achieving low disease activity or remission in patients with the AA genotype, both at 12\u00a0months and at the last available follow-up.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_almed-2025-0180_abs_004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This study highlights the potential of pharmacogenetics to personalize RA treatment by establishing, for the first time, that specific genetic variants involved in immune response may significantly influence the efficacy of JAK inhibitors. These findings open new perspectives for optimizing therapeutic decisions, although further studies are needed to validate\u00a0them.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/almed-2025-0180","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T10:08:52Z","timestamp":1777284532000},"page":"124-131","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacogenetic biomarkers for predicting therapeutic response to JAK inhibitors in rheumatoid arthritis"],"prefix":"10.1515","volume":"7","author":[{"given":"Chamaida","family":"Plasencia-Rodr\u00edguez","sequence":"first","affiliation":[{"name":"Rheumatology Department , La Paz University Hospital , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marta","family":"Novella-Navarro","sequence":"additional","affiliation":[{"name":"Rheumatology Department , La Paz University Hospital , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Juan Luis","family":"Valdivieso Shephard","sequence":"additional","affiliation":[{"name":"Pharmacogenetics Unit , La Paz University Hospital , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ana","family":"Mart\u00ednez-Feito","sequence":"additional","affiliation":[{"name":"Immunology , La Paz University Hospital , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keren","family":"Reche-Yebra","sequence":"additional","affiliation":[{"name":"Immunology , La Paz University Hospital , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manuel","family":"Ju\u00e1rez-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Rheumatology Department , La Paz University Hospital , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandro","family":"Villalba-Yll\u00e1n","sequence":"additional","affiliation":[{"name":"Rheumatology Department , La Paz University Hospital , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tania S.","family":"Rubio-Lepe","sequence":"additional","affiliation":[{"name":"Pharmacogenetics Unit , La Paz University Hospital , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pedro","family":"Arias","sequence":"additional","affiliation":[{"name":"Pharmacogenetics Unit , La Paz University Hospital , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria Lucia","family":"Collada S\u00e1nchez","sequence":"additional","affiliation":[{"name":"Servicio de Farmacia Hospitalaria, La Paz University Hospital , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Susana","family":"Martin-L\u00f3pez","sequence":"additional","affiliation":[{"name":"Pharmacogenetics Unit , La Paz University Hospital , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itsaso","family":"Losantos-Garc\u00eda","sequence":"additional","affiliation":[{"name":"Biostatistics Platform, La Paz University Hospital Research Institute (IdiPAZ) , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto M.","family":"Borobia","sequence":"additional","affiliation":[{"name":"Pharmacogenetics Unit , La Paz University Hospital , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3331-2161","authenticated-orcid":false,"given":"Roc\u00edo","family":"Rosas-Alonso","sequence":"additional","affiliation":[{"name":"Pharmacogenetics Unit , La Paz University Hospital , Madrid , Spain"},{"name":"Biomarkers and Experimental Therapeutics in Cancer, La Paz University Hospital Research Institute (IdiPAZ) , Madrid , Spain"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2026,4,23]]},"reference":[{"key":"2026051310150647606_j_almed-2025-0180_ref_001","doi-asserted-by":"crossref","unstructured":"Aletaha, D, Smolen, JS. Diagnosis and management of rheumatoid arthritis: a review. JAMA 2018;320:1360\u201372. https:\/\/doi.org\/10.1001\/jama.2018.13103.","DOI":"10.1001\/jama.2018.13103"},{"key":"2026051310150647606_j_almed-2025-0180_ref_002","doi-asserted-by":"crossref","unstructured":"Harre, U, Schett, G. Cellular and molecular pathways of structural damage in rheumatoid arthritis. Semin Immunopathol 2017;39:355\u201363. https:\/\/doi.org\/10.1007\/s00281-017-0634-0.","DOI":"10.1007\/s00281-017-0634-0"},{"key":"2026051310150647606_j_almed-2025-0180_ref_003","doi-asserted-by":"crossref","unstructured":"Seoane-Mato, D, Sanchez-Piedra, C, Silva-Fernandez, L, Sivera, F, Blanco, FJ, Perez Ruiz, F, et al.. Prevalence of rheumatic diseases in adult population in Spain (EPISER 2016 study): Aims and methodology. Reumatol Clin (Engl Ed) 2019;15:90\u20136. https:\/\/doi.org\/10.1016\/j.reumae.2018.10.004.","DOI":"10.1016\/j.reumae.2018.10.004"},{"key":"2026051310150647606_j_almed-2025-0180_ref_004","doi-asserted-by":"crossref","unstructured":"Klareskog, L, Catrina, AI, Paget, S. Rheumatoid arthritis. Lancet 2009;373:659\u201372. https:\/\/doi.org\/10.1016\/s0140-6736(09)60008-8.","DOI":"10.1016\/S0140-6736(09)60008-8"},{"key":"2026051310150647606_j_almed-2025-0180_ref_005","doi-asserted-by":"crossref","unstructured":"Chen, SJ, Lin, GJ, Chen, JW, Wang, KC, Tien, CH, Hu, CF, et al.. Immunopathogenic mechanisms and novel immune-modulated therapies in rheumatoid arthritis. Int J Mol Sci 2019;20:1332. https:\/\/doi.org\/10.3390\/ijms20061332.","DOI":"10.3390\/ijms20061332"},{"key":"2026051310150647606_j_almed-2025-0180_ref_006","doi-asserted-by":"crossref","unstructured":"Nam, JL, Takase-Minegishi, K, Ramiro, S, Chatzidionysiou, K, Smolen, JS, van der Heijde, D, et al.. Efficacy of biological disease-modifying antirheumatic drugs: a systematic literature review informing the 2016 update of the EULAR recommendations for the management of rheumatoid arthritis. Ann Rheum Dis 2017;76:1113\u201336. https:\/\/doi.org\/10.1136\/annrheumdis-2016-210713.","DOI":"10.1136\/annrheumdis-2016-210713"},{"key":"2026051310150647606_j_almed-2025-0180_ref_007","doi-asserted-by":"crossref","unstructured":"Abbasi, M, Mousavi, MJ, Jamalzehi, S, Alimohammadi, R, Bezvan, MH, Mohammadi, H, et al.. Strategies toward rheumatoid arthritis therapy; the old and the new. J\u00a0Cell Physiol 2019;234:10018\u201331. https:\/\/doi.org\/10.1002\/jcp.27860.","DOI":"10.1002\/jcp.27860"},{"key":"2026051310150647606_j_almed-2025-0180_ref_008","doi-asserted-by":"crossref","unstructured":"Aaltonen, KJ, Ylikyla, S, Tuulikki Joensuu, J, Isomaki, P, Pirila, L, Kauppi, M, et al.. Efficacy and effectiveness of tumour necrosis factor inhibitors in the treatment of rheumatoid arthritis in randomized controlled trials and routine clinical practice. Rheumatology 2017;56:725\u201335. https:\/\/doi.org\/10.1093\/rheumatology\/kew467.","DOI":"10.1093\/rheumatology\/kew467"},{"key":"2026051310150647606_j_almed-2025-0180_ref_009","doi-asserted-by":"crossref","unstructured":"Favalli, EG, Raimondo, MG, Becciolini, A, Crotti, C, Biggioggero, M, Caporali, R. The management of first-line biologic therapy failures in rheumatoid arthritis: current practice and future perspectives. Autoimmun Rev 2017;16:1185\u201395. https:\/\/doi.org\/10.1016\/j.autrev.2017.10.002.","DOI":"10.1016\/j.autrev.2017.10.002"},{"key":"2026051310150647606_j_almed-2025-0180_ref_010","doi-asserted-by":"crossref","unstructured":"Smolen, JS, Landewe, RBM, Bijlsma, JWJ, Burmester, GR, Dougados, M, Kerschbaumer, A, et al.. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 2020;79:685\u201399. https:\/\/doi.org\/10.1136\/annrheumdis-2019-216655.","DOI":"10.1136\/annrheumdis-2019-216655"},{"key":"2026051310150647606_j_almed-2025-0180_ref_011","doi-asserted-by":"crossref","unstructured":"Tornero Molina, J, Sanmarti Sala, R, Rodriguez Valverde, V, Martin Mola, E, Marenco de la Fuente, JL, Gonzalez Alvaro, I, et al.. [Update of the consensus statement of the Spanish Society of Rheumatology on the management of biologic therapies in rheumatoid arthritis]. Reumatol Clin 2010;6:23\u201336. https:\/\/doi.org\/10.1016\/s2173-5743(10)70006-x.","DOI":"10.1016\/S2173-5743(10)70006-X"},{"key":"2026051310150647606_j_almed-2025-0180_ref_012","doi-asserted-by":"crossref","unstructured":"Szekanecz, Z, Buch, MH, Charles-Schoeman, C, Galloway, J, Karpouzas, GA, Kristensen, LE, et al.. Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician. Nat Rev Rheumatol 2024;20:101\u201315. https:\/\/doi.org\/10.1038\/s41584-023-01062-9.","DOI":"10.1038\/s41584-023-01062-9"},{"key":"2026051310150647606_j_almed-2025-0180_ref_013","doi-asserted-by":"crossref","unstructured":"Katchamart, W, Johnson, S, Lin, HJ, Phumethum, V, Salliot, C, Bombardier, C. Predictors for remission in rheumatoid arthritis patients: a systematic review. Arthritis Care Res (Hoboken) 2010;62:1128\u201343. https:\/\/doi.org\/10.1002\/acr.20188.","DOI":"10.1002\/acr.20188"},{"key":"2026051310150647606_j_almed-2025-0180_ref_014","doi-asserted-by":"crossref","unstructured":"Kanjana, K, Chevaisrakul, P, Matangkasombut, P, Paisooksantivatana, K, Lumjiaktase, P. Inhibitory activity of FOXP3+ regulatory T\u00a0cells reveals high specificity for displaying immune tolerance in remission state rheumatoid arthritis. Sci Rep 2020;10:19789. https:\/\/doi.org\/10.1038\/s41598-020-76168-1.","DOI":"10.1038\/s41598-020-76168-1"},{"key":"2026051310150647606_j_almed-2025-0180_ref_015","doi-asserted-by":"crossref","unstructured":"Yilmaz-Oner, S, Ozen, G, Can, M, Atagunduz, P, Direskeneli, H, Inanc, N. Biomarkers in remission according to different criteria in patients with rheumatoid arthritis. J\u00a0Rheumatol 2015;42:2066\u201370. https:\/\/doi.org\/10.3899\/jrheum.150478.","DOI":"10.3899\/jrheum.150478"},{"key":"2026051310150647606_j_almed-2025-0180_ref_016","doi-asserted-by":"crossref","unstructured":"Teitsma, XM, Jacobs, JWG, de Jong, PHP, Hazes, JMW, Weel, A, Welsing, PMJ, et al.. Adding baseline protein biomarkers to clinical predictors does not enhance prediction of treatment response to a methotrexate strategy in early rheumatoid arthritis. Ann Rheum Dis 2019;78:142\u20134. https:\/\/doi.org\/10.1136\/annrheumdis-2018-213767.","DOI":"10.1136\/annrheumdis-2018-213767"},{"key":"2026051310150647606_j_almed-2025-0180_ref_017","doi-asserted-by":"crossref","unstructured":"Yap, HY, Tee, SZ, Wong, MM, Chow, SK, Peh, SC, Teow, SY. Pathogenic role of immune cells in rheumatoid arthritis: implications in clinical treatment and biomarker development. Cells 2018;7:161. https:\/\/doi.org\/10.3390\/cells7100161.","DOI":"10.3390\/cells7100161"},{"key":"2026051310150647606_j_almed-2025-0180_ref_018","doi-asserted-by":"crossref","unstructured":"Rosas-Alonso, R, Queiruga, J, Arias, P, Del Monte, A, Yuste, F, Rodriguez-Antolin, C, et al.. Analytical validation of a laboratory-development multigene pharmacogenetic assay. Pharmacogenet Genomics 2021;31:177\u201384. https:\/\/doi.org\/10.1097\/fpc.0000000000000438.","DOI":"10.1097\/FPC.0000000000000438"},{"key":"2026051310150647606_j_almed-2025-0180_ref_019","unstructured":"van Riel, PL, Renskers, L. The disease activity score (DAS) and the disease activity score using 28 joint counts (DAS28) in the management of rheumatoid arthritis. Clin Exp Rheumatol 2016;34:S40\u20134."},{"key":"2026051310150647606_j_almed-2025-0180_ref_020","doi-asserted-by":"crossref","unstructured":"Hartwig, T, Montinaro, A, von Karstedt, S, Sevko, A, Surinova, S, Chakravarthy, A, et al.. The TRAIL-induced cancer secretome promotes a tumor-supportive immune microenvironment via CCR2. Mol Cell 2017;65:730\u201342.e5. https:\/\/doi.org\/10.1016\/j.molcel.2017.01.021.","DOI":"10.1016\/j.molcel.2017.01.021"},{"key":"2026051310150647606_j_almed-2025-0180_ref_021","doi-asserted-by":"crossref","unstructured":"Morales-Lara, MJ, Conesa-Zamora, P, Santaclara, V, Torres-Moreno, D, Pedrero, F, Corral, J, et al.. Role of TRAILR1 and TNFR1A polymorphisms in the susceptibility and pharmacogenetics of rheumatoid arthritis and ankylosing spondylitis patients treated with infliximab. J\u00a0Transl Med 2010;8:P50. https:\/\/doi.org\/10.1186\/1479-5876-8-S1-P50.2010.","DOI":"10.1186\/1479-5876-8-S1-P51"},{"key":"2026051310150647606_j_almed-2025-0180_ref_022","doi-asserted-by":"crossref","unstructured":"Morales-Lara, MJ, Canete, JD, Torres-Moreno, D, Hernandez, MV, Pedrero, F, Celis, R, et al.. Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis. Joint Bone Spine 2012;79:591\u20136. https:\/\/doi.org\/10.1016\/j.jbspin.2012.02.003.","DOI":"10.1016\/j.jbspin.2012.02.003"},{"key":"2026051310150647606_j_almed-2025-0180_ref_023","doi-asserted-by":"crossref","unstructured":"Schwartz, DM, Kanno, Y, Villarino, A, Ward, M, Gadina, M, O\u2019Shea, JJ. JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov 2017;17:78. https:\/\/doi.org\/10.1038\/nrd.2017.267.","DOI":"10.1038\/nrd.2017.267"},{"key":"2026051310150647606_j_almed-2025-0180_ref_024","doi-asserted-by":"crossref","unstructured":"Nimmerjahn, F, Ravetch, JV. Fcgamma receptors as regulators of immune responses. Nat Rev Immunol 2008;8:34\u201347. https:\/\/doi.org\/10.1038\/nri2206.","DOI":"10.1038\/nri2206"},{"key":"2026051310150647606_j_almed-2025-0180_ref_025","doi-asserted-by":"crossref","unstructured":"Thaler, E, Bublitz, M, Wipplinger, M, Gassner, C, Ulmer, H. Association of FCGR2A rs1801274 and FCGR3A rs396991 polymorphisms with various autoimmune diseases: a meta-analysis. Front Immunol 2025;16:1661502. https:\/\/doi.org\/10.3389\/fimmu.2025.1661502.","DOI":"10.3389\/fimmu.2025.1661502"},{"key":"2026051310150647606_j_almed-2025-0180_ref_026","doi-asserted-by":"crossref","unstructured":"Montes, A, Perez-Pampin, E, Narvaez, J, Canete, JD, Navarro-Sarabia, F, Moreira, V, et al.. Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis. Pharmacogenet Genomics 2014;24:238\u201345. https:\/\/doi.org\/10.1097\/fpc.0000000000000042.","DOI":"10.1097\/FPC.0000000000000042"},{"key":"2026051310150647606_j_almed-2025-0180_ref_027","doi-asserted-by":"crossref","unstructured":"Marquez, PN, Maldonado, MMDM, Perez Ramirez, C, Martinez Martinez, F, Martinez de la Plata, JE, Daddaoua, A, et al.. Influence of the FCGR2A rs1801274 and FCGR3A rs396991 polymorphisms on response to abatacept in patients with rheumatoid arthritis. J\u00a0Pers Med 2021;11:573.","DOI":"10.3390\/jpm11060573"},{"key":"2026051310150647606_j_almed-2025-0180_ref_028","doi-asserted-by":"crossref","unstructured":"Davila-Fajardo, CL, van der Straaten, T, Baak-Pablo, R, Medarde Caballero, C, Cabeza Barrera, J, Huizinga, TW, et al.. FcGR genetic polymorphisms and the response to adalimumab in patients with rheumatoid arthritis. Pharmacogenomics 2015;16:373\u201381. https:\/\/doi.org\/10.2217\/pgs.14.178.","DOI":"10.2217\/pgs.14.178"},{"key":"2026051310150647606_j_almed-2025-0180_ref_029","doi-asserted-by":"crossref","unstructured":"Jimenez Morales, A, Maldonado-Montoro, M, Martinez de la Plata, JE, Perez Ramirez, C, Daddaoua, A, Alarcon Payer, C, et al.. FCGR2A\/FCGR3A gene polymorphisms and clinical variables as predictors of response to tocilizumab and rituximab in patients with rheumatoid arthritis. J\u00a0Clin Pharmacol 2019;59:517\u201331. https:\/\/doi.org\/10.1002\/jcph.1341.","DOI":"10.1002\/jcph.1341"},{"key":"2026051310150647606_j_almed-2025-0180_ref_030","doi-asserted-by":"crossref","unstructured":"Antonatos, C, Stavrou, EF, Evangelou, E, Vasilopoulos, Y. Exploring pharmacogenetic variants for predicting response to anti-TNF therapy in autoimmune diseases: a meta-analysis. Pharmacogenomics 2021;22:435\u201345. https:\/\/doi.org\/10.2217\/pgs-2021-0019.","DOI":"10.2217\/pgs-2021-0019"},{"key":"2026051310150647606_j_almed-2025-0180_ref_031","doi-asserted-by":"crossref","unstructured":"Maxwell, JR, Potter, C, Hyrich, KL, Biologics in Rheumatoid Arthritis\u00a0Genetics and Genomics Study Syndicate, Barton, A, Worthington, J, Isaacs, JD, et al.. Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis. Hum Mol Genet 2008;17:3532\u20138. https:\/\/doi.org\/10.1093\/hmg\/ddn245.","DOI":"10.1093\/hmg\/ddn245"},{"key":"2026051310150647606_j_almed-2025-0180_ref_032","doi-asserted-by":"crossref","unstructured":"Canet, LM, Filipescu, I, Caliz, R, Lupianez, CB, Canhao, H, Escudero, A, et al.. Genetic variants within the TNFRSF1B gene and susceptibility to rheumatoid arthritis and response to anti-TNF drugs: a multicenter study. Pharmacogenet Genomics 2015;25:323\u201333. https:\/\/doi.org\/10.1097\/fpc.0000000000000140.","DOI":"10.1097\/FPC.0000000000000140"},{"key":"2026051310150647606_j_almed-2025-0180_ref_033","unstructured":"Rooryck, C, Barnetche, T, Richez, C, Laleye, A, Arveiler, B, Schaeverbeke, T. Influence of FCGR3A-V212F and TNFRSF1B-M196R genotypes in patients with rheumatoid arthritis treated with infliximab therapy. Clin Exp Rheumatol 2008;26:340\u20132."}],"container-title":["Advances in Laboratory Medicine \/ Avances en Medicina de Laboratorio"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/almed-2025-0180\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/almed-2025-0180\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,13]],"date-time":"2026-05-13T10:16:19Z","timestamp":1778667379000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/almed-2025-0180\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,23]]},"references-count":33,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,4,28]]},"published-print":{"date-parts":[[2026,5,12]]}},"alternative-id":["10.1515\/almed-2025-0180"],"URL":"https:\/\/doi.org\/10.1515\/almed-2025-0180","relation":{},"ISSN":["2628-491X"],"issn-type":[{"value":"2628-491X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,23]]}}}